ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,705.00
32.00 (1.91%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  32.00 1.91% 1,705.00 1,701.00 1,701.50 1,718.50 1,673.00 1,685.50 5,853,296 16:35:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.21 70.03B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,673p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.03 billion. Gsk has a price to earnings ratio (PE ratio) of 14.21.

Gsk Share Discussion Threads

Showing 32776 to 32799 of 33125 messages
Chat Pages: Latest  1313  1312  1311  1310  1309  1308  1307  1306  1305  1304  1303  1302  Older
DateSubjectAuthorDiscuss
13/12/2023
11:30
looking good here to test top of range again
supermarky
12/12/2023
08:10
Japan's Ministry of Health, Labour and Welfare accepts Arexvy regulatory application to prevent RSV disease in adults aged 50-59 at increased risk

-- Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59

-- Adults aged 50 and above with certain underlying medical conditions are at increased risk for RSV disease

-- GSK is the first company to seek regulatory approval to extend RSV vaccination to this population

tradermichael
12/12/2023
07:07
uk.advfn.com/stock-market/london/gsk-GSK/share-news/GSK-PLC-Japan-accepts-Arexvy-filing-for-at-risk-adults/92781084
garycook
11/12/2023
13:28
Cheer up guys, it's up a whole penny.
mister md
11/12/2023
10:47
Down she goes on not so good news .
abdullla
11/12/2023
07:27
Good news = bad news for share price , typically !
alibizzle
01/12/2023
11:55
Very short term moves are nearly all random, meaning as you say that there is no reason, but the long term decline is due to the company's long term poor performance.
anhar
01/12/2023
11:14
What rubbish performance share price lost 20p for no reason atall.
abdullla
30/11/2023
16:50
I've been sensing that for 21 years .....
tradermichael
30/11/2023
11:52
GSK up 24c in the after hours US market. I am sensing sentiment may be changing here at £14 is acting as support.
beergut
30/11/2023
11:19
I thought as much and thanks
beergut
30/11/2023
10:42
That is a lot of LTIPs!
alphorn
30/11/2023
10:27
"The notification relates to the transfer at market value of 20.0 million treasury shares held by GSK plc to GSK plc's UK Employee Share Ownership Trust required to meet the expected requirement arising from awards made under GSK plc's Long Term Incentive Plan until 2026 vestings."
patientcapital
30/11/2023
08:38
Who is the new shareholder as it looks like GSK, but I'm look at my phone screen
beergut
29/11/2023
08:37
You'd think so. However, it didn't seem to benefit the GSK price when the pound dropped from 1.27 to 1.23 ..... ;0)
tradermichael
29/11/2023
07:50
I assume GSK will be negatively effected by $ weakness. Like all companies with $ income. Any thoughts
beergut
27/11/2023
08:41
GSK has disclosed encouraging results from its phase III DREAMM-7 trial, revealing that Blenrep (belantamab mafodotin) has shown effectiveness as a second-line treatment for relapsed or refractory multiple myeloma.
tradermichael
23/11/2023
16:31
Hopefully can back to £15-16 in January 2024. It's underperformed for way too long . Still think haleon will be subject to a takeover in 2024 so my considerable GSK shares losses can perhaps be mitigated with share price jump from there . Basically clutching at straws
alibizzle
23/11/2023
12:03
A large number of new entities at Phase III trials. Many are destined to be first/best 'in class'. This will eventually be recognised by the 'market'.
tradermichael
22/11/2023
10:14
If only they could stop inventing new drugs. It drives the price down every time.
beergut
22/11/2023
08:02
GSK3437949 Malaria next generation (fractional dose)?
tradermichael
21/11/2023
16:07
Word on the street have a game changing malaria vacine in final trails.
giltedge1
17/11/2023
10:28
Money moving to APH
blackhorse23
16/11/2023
11:43
From now ?
panache1
Chat Pages: Latest  1313  1312  1311  1310  1309  1308  1307  1306  1305  1304  1303  1302  Older

Your Recent History

Delayed Upgrade Clock